Jim Cramer praises Walgreens new CEO pick, says buy the stock ‘perhaps aggressively’

Jim Cramer praises Walgreens new CEO pick, says buy the stock ‘perhaps aggressively’


Cramer’s Mad Dash on Walgreens Boots: The stock should be bought 'perhaps aggressively'

CNBC’s Jim Cramer on Wednesday praised the incoming CEO of Walgreens Boots Alliance, saying industry veteran Tim Wentworth is the right choice to lead the struggling pharmacy chain in its transition to offering more health-care services.

“This guy is the real deal. I just salute him and think he can take you to a higher price, and the stock should be bought — perhaps aggressively,” Cramer said on “Squawk on the Street.”

Wentworth, whose appointment was announced Thursday night, previously served as CEO of Express Scripts, a pharmacy benefits manager acquired by health insurer Cigna in 2018. He stayed on for a few years as an executive at Cigna.

If you like this story, sign up for Jim Cramer’s Top 10 Morning Thoughts on the Market email newsletter for free.

Wentworth’s first day at Walgreens is set for Oct. 23, less than two months after former chief executive Roz Brewer left her post. The company said it was seeking a new CEO who had “deep” experience in the health-care industry.

Shares of Walgreens rose more than 1% Wednesday, to $22.66. However, so far in 2023, the Dow Jones Industrial Average constituent is down nearly 40%.

“I like Wentworth, and there is now hope for a stock that I held no hope for,” Cramer said.

The CNBC Investing Club portfolio does not own Walgreens but does have some exposure to health-care services via Amazon, which bought a primary care company and has an online prescription drug store.

Here’s a full list of the stocks in Jim’s Charitable Trust, the portfolio used by the CNBC Investing Club.



Source

Rocket Lab rises 5% on record third-quarter revenue, launch backlog
Health

Rocket Lab rises 5% on record third-quarter revenue, launch backlog

Rocket Lab‘s stock rose as much as 5% on Tuesday after the space company posted record revenues in the third-quarter as it scoops up more launch deals and builds its backlog. The company, which makes satellites and rockets and provides launch services to its customers, on Monday reported revenue of $155 million for the period. […]

Read More
Millions more Americans could access obesity drugs after Trump’s deals with Eli Lilly, Novo Nordisk
Health

Millions more Americans could access obesity drugs after Trump’s deals with Eli Lilly, Novo Nordisk

US President Donald Trump makes an announcement in the Oval Office of the White House in Washington, DC on Nov. 6, 2025. Andrew Caballero-Reynolds | AFP | Getty Images President Donald Trump on Thursday struck landmark deals with Eli Lilly and Novo Nordisk that could mark a turning point in how many people can access […]

Read More
Startup Omada Health to start prescribing GLP-1s, other obesity medications as membership grows 
Health

Startup Omada Health to start prescribing GLP-1s, other obesity medications as membership grows 

The Omada Health logo is displayed on a smartphone screen. Sopa Images | Lightrocket | Getty Images Virtual care company Omada Health on Thursday said it will start prescribing GLP-1s and other obesity drugs and helping patients manage those medications. Omada plans to expand the offerings under its weight management program as its membership grows […]

Read More